Navigation Links
PSivida, Pfizer Ink $165 Million Licensing Pact

Perth-based bio-nanotech major, pSivida Limited has signed an exclusive worldwide Collaborative Research and License Agreement with Pfizer for its controlled// drug delivery technologies, including the Medidur technology in ophthalmic applications.

Under the terms of the agreement, pSivida will receive up to $155 million in development and sales related milestones.

Pfizer will have an exclusive license to market all products developed as part of this research collaboration in ophthalmic applications and will pay pSivida a royalty on net sales of those products.

In addition to the development and sales milestones and payment of the cost of the joint research program, Pfizer has agreed to invest $5 million in ordinary shares of pSivida upon entering into the license agreement, the proceeds of which will be held in escrow until such proceeds can be used (together with other cash available to pSivida) to redeem an outstanding convertible note.

Dr Paul Ashton, Managing Director, pSivida, said, “We believe this collaboration is another significant validation of the drug delivery systems that pSivida has been developing since its founding. We plan to pursue development and additional collaborations exploiting our innovative drug delivery technologies in other parts of the body.”

Medidur is a tiny, injectable device designed for the sustained release of drugs and is currently being studied for the treatment of Diabetic Macular Edema (DME).

Source: BioSpectrum/
'"/>




Page: 1

Related medicine news :

1. Pfizer unveils anti-smoking drug
2. The Effectiveness Of The Breast Cancer Drug By Pfizer
3. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
4. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
5. Pfizer’s Eraxis Approved By The FD
6. Pfizer Launches Viagra For Lung Disease In UK
7. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. FDA Approves Pfizer’s Anti-smoking Dru
10. Pfizer vouches safety of long-term inhaled insulin.
11. NICE Setback Rules for Pfizers Inhaled Insulin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, ... published a new eBook titled “ 5 Questions to Ask Before Entering the ... on the Genetic Test Evaluation (GTE) team, the book explores the various types ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer of ... to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant ... , With trendy looks hitting the medical community, UA Flex is for the medical ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
Breaking Medicine Technology: